Each new edition of IMF captures changes to the medicines licensed and marketed in Ireland since the previous edition.
It is important to note that the vast majority of updates occur in the prescribing and safety information for drug-classes and for individual medications. Such updates might include changes to recommended dosage, special precautions, potential drug interactions as well as practical details including reimbursement status and presentations available for each drug.
Therefore always using the most up to date IMF is strongly recommended.
New Molecules, New Combinations
Allergic Rhinitis: Mometasone, Olopatadine
Atopic Dermatitis: Abrocitinib
Atopic Dermatitis: Tralokinumab
Dermatology: Deoxycholic Acid
Ophthalmology: Dexamethasone + Levofloxacin
Parkinson’s Disease: Opicapone
Prostate Cancer: Apalutamide
Psoriatic Conditions: Risankizumab
Psoriatic Conditions: Tildrakizumab
Vaccines: Pneumococcal polysaccharide vaccine (15-valent)
Vaccines: Varicella Zoster Vaccine (recombinant, adjuvanted)
New Generic Equivalents
IMF is unique: it includes all generic medicines licensed and marketed in Ireland in addition to the original branded products. There are 11 new such medicines included in this new edition. Each new product is detailed in the relevant chapter.
New Formulations, Presentations
In addition to new medicines, a number of existing medicines have been updated with new formulations, new strengths, or new presentations. Details for each of these changes are included in the relevant entries.